News
SNZZF
0.700
NaN%
--
Senzime Establishes Nomination Committee for 2026 AGM
TipRanks · 11/03 14:04
Senzime AB Reports Strong Q3 2025 Growth
TipRanks · 10/30 04:55
Senzime AB Q3 Sales Rise 52% to SEK 26.5 Million
Reuters · 10/29 07:30
BRIEF-Senzime Q3 Sales SEK 26.478 Million
Reuters · 10/29 07:30
Senzime Unveils EMGINE Software to Enhance Neuromuscular Monitoring
Barchart · 10/09 06:40
Senzime Embraces New Pediatric Guidelines for EMG-Based Monitoring
Barchart · 10/04 08:14
Senzime Secures Major U.S. Defense Contract for TetraGraph System
TipRanks · 09/17 11:33
Weekly Report: what happened at SNZZF last week (0908-0912)?
Weekly Report · 09/15 12:07
Senzime to Present at Pareto Healthcare Conference
TipRanks · 09/12 08:32
Senzime Integrates TetraGraph System with Mindray Monitors
TipRanks · 09/12 07:33
Senzime Poised for Growth with New Japanese Anesthesia Guidelines
TipRanks · 09/09 09:33
Weekly Report: what happened at SNZZF last week (0901-0905)?
Weekly Report · 09/08 12:10
Senzime to Present at European Growth Virtual Investor Conference
TipRanks · 09/08 11:32
California University Hospital System Adopts Senzime’s TetraGraph for Neuromuscular Monitoring
TipRanks · 09/04 15:02
Weekly Report: what happened at SNZZF last week (0825-0829)?
Weekly Report · 09/01 12:03
Weekly Report: what happened at SNZZF last week (0818-0822)?
Weekly Report · 08/25 12:19
Weekly Report: what happened at SNZZF last week (0811-0815)?
Weekly Report · 08/18 12:07
Weekly Report: what happened at SNZZF last week (0804-0808)?
Weekly Report · 08/11 12:17
More
Webull provides a variety of real-time SNZZF stock news. You can receive the latest news about Senzime Ab through multiple platforms. This information may help you make smarter investment decisions.
About SNZZF
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.